Sionna raises $182M for cystic fibrosis drugs different from Vertex's approach
06 Mar 2024
Sionna Therapeutics has raised $182 million in a Series C to test its small molecules for cystic fibrosis by targeting the mutated region of the protein at the root of the disease, unlike Vertex Pharmaceuticals, the drugmaker that pioneered medicines for the field.
The oversubscribed round was led by Enavate Sciences, part of the Patient Square Capital portfolio, the Boston-based biotech said Wednesday morning. The investor has also backed Sam Waksal’s ROCK2 biotech Graviton Bioscience and TYK2 startup Sudo Biosciences in recent months.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.